Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants

What Was Tested

This randomized controlled trial paper looks at Cagrilintide and Amylin (Islet Amyloid Polypeptide).

The combination of cagrilintide and semaglutide (CagriSema) is being developed for the treatment of obesity and type 2 diabetes.

The objective of this thorough QT study was to confirm that cagrilintide does not result in a clinically relevant prolongation in cardiac repolarization compared with placebo.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The participants were allocated by chance, so the Cagrilintide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Cagrilintide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Cagrilintide group a baseline to be compared against.

In the crossover set-up each of the participants took both Cagrilintide and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Electrocardiography, Glucagon-Like Peptides, Healthy Volunteers, Heart Rate, Hypoglycemic Agents and Long QT Syndrome.

The authors tagged it with the keywords antidiabetic drug, antiobesity drug, clinical trial, drug development and randomized trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cagrilintide and Amylin (Islet Amyloid Polypeptide).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Cagrilintide compound page and the Amylin (Islet Amyloid Polypeptide) compound page.